OncLive: Dr. Mesa on the rationale for the earlier use of ruxolitinib in myelofibrosis
October 19, 2020
In this video, Ruben Mesa, MD, executive director of the Mays Cancer, discusses the rationale for the earlier use of ruxolitinib (Jakafi) in myelofibrosis. Watch the interview.